Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST-Segment–Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform

Marc J. George, MBChB, PhD; Ola Kleveland, MD, PhD; Jorge Garcia-Hernandez, MSc; Jutta Palmen, MSc; Ruth Lovering, PhD; Rune Wiseth, MD, PhD; Pål Aukrust, MD, PhD; Jorgen Engmann, MSc; Jan Kristian Damås, MD, PhD; Aroon D. Hingorani, BM, BCh, PhD; Lars Gullestad, MD, PhD; Juan P. Casas, MD, PhD; Thor Ueland, PhD

BACKGROUND: Interleukin 6 concentration is associated with myocardial injury, heart failure, and mortality after myocardial infarction. In the Norwegian tocilizumab non–ST-segment–elevation myocardial infarction trial, the first randomized trial of interleukin 6 blockade in myocardial infarction, concentration of both C-reactive protein and troponin T were reduced in the active treatment arm. In this follow-up study, an aptamer-based proteomic approach was employed to discover additional plasma proteins modulated by tocilizumab treatment to gain novel insights into the effects of this therapeutic approach.

METHODS AND RESULTS: Plasma from percutaneous coronary intervention–treated patients, 24 in the active intervention and 24 in the placebo-control arm, drawn 48 hours postrandomization were randomly selected for analysis with the SOMAscan assay. Employing slow off-rate aptamers, the relative abundance of 1074 circulating proteins was measured. Proteins identified as being significantly different between groups were subsequently measured by enzyme immunoassay in the whole trial cohort (117 patients) at all time points (days 1–3 [7 time points] and 3 and 6 months). Five proteins identified by the SOMAscan assay, and subsequently confirmed by enzyme immunoassay, were significantly altered by tocilizumab administration. The acute-phase proteins lipopolysaccharide-binding protein, hepcidin, and insulin-like growth factor-binding protein 4 were all reduced during the hospitalization phase, as was the monocyte chemoattractant C-C motif chemokine ligand 23. Proteinase 3, released primarily from neutrophils, was significantly elevated.

CONCLUSIONS: Employing the SOMAscan aptamer-based proteomics platform, 5 proteins were newly identified that are modulated by interleukin 6 antagonism and may mediate the therapeutic effects of tocilizumab in non–ST-segment–elevation myocardial infarction.

Key Words: inflammation ■ interleukin ■ myocardial infarction ■ proteomics
Interleukin 6 antagonism with tocilizumab in non-ST-segment-elevation myocardial infarction reduces troponin T. However, we have hitherto been unable to identify cytokines or other molecules that could contribute to this effect.

Employing the powerful SOMAscan proteomics platform, we newly identified 5 proteins that are modulated by interleukin 6 antagonism in non-ST-segment-elevation myocardial infarction. The acute-phase proteins lipopolysaccharide-binding protein, hepcidin, and insulin-like growth factor-binding protein 4 were all reduced during the hospitalization phase, as was the monocyte chemotactant C-C motif chemokine ligand 23.

Protease 3, released primarily from neutrophils, was significantly elevated.

These proteins may be secondary downstream mediators of the beneficial effect of tocilizumab.

As the interest in targeting inflammatory cytokines such as interleukin 6 in coronary disease grows, proteomics can aid in our understanding of the results of this approach and may lead to the identification of new targets and more effective therapeutics.

Nonstandard Abbreviations and Acronyms

| Acronym | Definition |
|---------|------------|
| ASSAIL-MI | Assessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction |
| C5A | complement component C5a anaphylatoxin |
| CAD | coronary artery disease |
| CCL23 | CC motif chemokine ligand 23 |
| CRP | C-reactive protein |
| CXCL | C-X-C motif chemokine ligand |
| EIA | enzyme immunoassay |
| HAMP | hepcidin antimicrobial peptide |
| hsTnT | high-sensitivity troponin T |
| IGFBP4 | insulin-like growth factor-binding protein 4 |
| IL | interleukin |
| LBP | lipopolysaccharide-binding protein |
| MI | myocardial infarction |
| NSTEMI | non-ST-segment-elevation myocardial infarction |
| NT-proBNP | N-terminal pro-B-type natriuretic peptide |
| PCI | percutaneous coronary intervention |
| PRTN3 | proteinase 3 |
| SerpinA3 | serpin family A member 3 |
| sgp130 | soluble glycoprotein 130 |
| sIL-6R | soluble interleukin 6 receptor |
| SOMAmers | slow off-rate aptamers |
| UPI | UniProt ID |
| VEGF | Vascular endothelial growth factor |
| WebGestalt | WEB-based Gene Set Analysis Toolkit |

METHODS

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Patients, Sample Collection, and Processing

Stored plasma samples from patients enrolled in the Norwegian tocilizumab NSTEMI trial included in...
the original trial analyses (117 patients) were used in this study. The trial was approved by the Regional Committee for Medical and Health Research Ethics of South-Eastern Norway and the Norwegian Medicines Agency, and conducted according to the Declaration of Helsinki. All participants provided written, informed consent. Plasma was obtained from peripheral venous blood drawn into EDTA tubes as previously described. For the discovery cohort, a total of 48 percutaneous coronary intervention (PCI)–treated patients (24 from the active intervention and 24 from the placebo-control arm) were selected at random, and plasma from patients obtained 48 hours post-randomization (during hospitalization) were analyzed with the commercially available SOMAscan assay. These patients were selected given that in the original study, a significant reduction in hsTnT was only observed in PCI-treated patients (71% of the cohort) and the greatest difference in CRP between groups was observed 48 hours post-randomization.

The SOMAscan assay is a sensitive, high-throughput assay employing slow off-rate aptamers (SOMAmers) that are single-stranded DNA molecules (approximately 40 mer in length) with specific affinity for the circulating proteins of interest. The “1.3k” assay with specific affinity throughput assay employing slow off-rate aptamers (SOMAmers) that are single-stranded DNA molecules (approximately 40 mer in length) with specific affinity for the circulating proteins of interest.

Samples were processed at the University College London with quality-control oversight from SomaLogic. Methods are described elsewhere. Briefly, the plasma was incubated with a mixture of biotin-labeled SOMAmers, followed by capture of all SOMAmer-protein complexes on streptavidin beads. After further processing, a mixture of free SOMAmers is produced that quantitatively reflects the protein concentrations in the original sample. The SOMAmers are subsequently hybridized to DNA oligonucleotides on an array. The assay signal is expressed as relative fluorescence units. SomaLogic also performs normalization to reduce intrasample bias and calibration procedures to decrease between-sample variability. After all quality-control procedures were completed, the relative abundance of 1074 proteins were available for each sample.

**Transformation of SOMAscan Data**

To enable statistical analysis, the distribution of relative fluorescence unit values was normalized by taking the natural log. This transformation was selected as it resulted in the greatest reduction in outliers, skewness, and kurtosis, and aided interpretability as compared with other transformations under consideration (Figure S1).

**SOMAscan Validation**

To assess the validity of the SOMAscan assay, the concentration of IL-6, sIL-6R, sgp130 (soluble glycoprotein 130), and CRP measured by other means in the placebo group of the original study were compared with measurements obtained using SOMAscan. The methods used for measurement of these proteins in the original study are described elsewhere. The linear correlation between these 4 analytes was assessed with Pearson correlation.

**Protein Discovery Using SOMAscan**

Independent samples t tests were performed to assess the mean differences in protein measurements between patients randomized to the tocilizumab and placebo groups. Post hoc correction for multiple comparisons was performed with Benjamini-Hochberg procedure with false discovery rate set to 0.1. The more liberal of these approaches (Benjamini-Hochberg) was selected given the exploratory nature of the study.

**Temporal Profile of Discovered Proteins Over the Entire Time Course**

To corroborate findings from the SOMAscan platform and to understand the full temporal profile of the proteins that were modulated by tocilizumab, these proteins were measured in the Norwegian tocilizumab NSTEMI trial cohort (tocilizumab n=58, placebo n=59) over the entire time course of the study. During the trial, blood samples were drawn prerandomization and at 6 time points after the administration of drug or placebo during the first 56 hours of hospitalization (day 1: evening; day 2: morning, afternoon, and evening; and day 3: morning and afternoon). Further samples were drawn at 3 and 6 months postrandomization. Plasma was stored in aliquots at −80°C until analyzed. The proteins were measured by enzyme immunoassay (EIA) using commercially available antibodies (Table S1). A commercially available CCL23 (C-C motif chemokine ligand 23) antibody was employed in the EIA, which recognizes both CCL23 and the splice variant Ck-beta-8-1, therefore only 1 measure, encompassing both of these proteins, was made. All proteins were analyzed in duplicate in a 384-well format using a combination of a SELMA pipetting robot (Analytik Jena AG) and a BioTek (BioTek Instruments, Inc) dispenser/washer. Absorption was read at 450 nm with wavelength correction set to 540 nm using an ELISA plate reader (BioTek). Intraassay and interassay coefficients were <10%.

**Statistical Analysis**

The effects of tocilizumab treatment on circulating levels of these proteins over time were evaluated by the
presence of a significant tocilizumab*time interaction with an ANOVA test using a mixed model with patient (intercept) as a random effect, while adjusting the fixed effects of tocilizumab treatment, time, and their interaction with baseline covariates. For these analyses, log-transformed values for all biomarkers were used to achieve normalization/near-normalization of distributions, and data are expressed as the back-transformed estimated marginal mean with 95% CIs. As well as analyzing the whole cohort, a subanalysis of patients treated with PCI versus untreated was also performed.

**Interaction Analysis**

To give further insight, the association between significantly regulated proteins and key variables measured in the original study was assessed. These variables include CRP, hsTnT, NT-proBNP (N-terminal pro-B-type natriuretic peptide), IL-6, and neutrophils. Log-transformed area under the curve values of each analyte during the acute phase (days 1–3) was used to assess associations. If no interaction with tocilizumab treatment was detected, Pearson regression coefficient for the whole population was reported. If an interaction with tocilizumab was present, Pearson regression coefficient within each group was reported.

**Functional Enrichment Analysis**

In order to understand how the proteins modified by tocilizumab correlate with its wider effects on the proteome, we performed a functional enrichment analysis. This involved comparing the list of proteins altered by tocilizumab with an uncorrected \( P \) value <0.05 (Table S2), excluding IL-6 and sIL-6R as they are directly modulated by tocilizumab, and SerpinA3 (serpin family A member 3) (discordant data from SOMAscan and EIA), to the list of 1054 proteins measured by the SOMAscan assay using WebGestalt (WEB-based Gene Set Analysis Toolkit). The analysis used Gene Ontology annotation and ontology files data accessed on January 14, 2019. We set WebGestalt to report the top 100 enriched biological processes and then applied the affinity propagation function to generate the final list. Biological processes that were not relevant, eg, "regulation of symbiosis," were excluded. Given the exploratory nature of this analysis, a false-discovery rate threshold was not set and enrichment was considered significant with \( P<0.05 \).

**RESULTS**

The 48 patients whose samples were included in the SOMAscan analysis did not differ significantly from the overall cohort, neither were there any differences between the study groups (Table 1). The mean age of the cohort was 56.8 years, 42 (87.5%) were men, 12 (25%) had diabetes mellitus, 22 (45.8%) were current smokers, and mean body mass index was 30.4 kg/m². Blood pressure at baseline was 138/83 mm Hg.

**SOMAscan Validation**

Correlations between the SOMAscan values and the equivalent measurements from the original study were IL-6 (\( r=0.52, P=0.008 \)), sIL-6R (\( r=0.54, P=0.006 \)), sgp130 (\( r=0.49, P=0.02 \)), and CRP (\( r=0.93, P<0.001 \)).

**Protein Discovery Using SOMAscan**

In the discovery cohort, 11 proteins were found to be significantly different between the tocilizumab and placebo groups using the SOMAscan assay (0.1 false discovery rate threshold of \( P=0.0005612 \) (Table 2).

| Table 1. Patient Demographics According to Treatment Group Between the Original Study and the Subset Used for the SOMAscan Assay |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                            | Discovery Population, N=48  | Original Study, N=117       |
| Placebo, n=24              | Placebo, n=59               |
| Active, n=24               | Active, n=58                |
| Risk factors baseline      |                            |                            |
| Age, mean (SD), y          | 56.1 (10.2)                 | 57.4 (7.2)                 |
| Women, No. (%)             | 3 (12.5)                    | 3 (12.5)                   |
| Body mass index, mean (SD), kg/m² | 30.5 (4.8)                 | 30.3 (3.4)                 |
| Diabetes mellitus, No. (%) | 7 (29.2)                    | 5 (20.8)                   |
| Current smoking, No. (%)   | 10 (41.7)                   | 12 (50)                    |
| PCI-treated                | 24 (100)                    | 24 (100)                   |
| Systolic BP, mm Hg, mean (SD) | 137.7 (16.7)                | 139.5 (21.7)               |
| Diastolic BP, mm Hg, mean (SD) | 81.7 (12.1)                 | 84.8 (12.0)                |

BP indicates blood pressure; PCI, percutaneous coronary intervention.
George et al Proteomic Analysis of IL-6 Antagonism in NSTEMI

Figure 1). Two of the identified proteins were sIL-6R (UniProt ID [UPI]: P08887) and IL-6 (UPI: P05231), both of which had been shown to be increased by the administration of tocilizumab in the original study. Therefore, the findings for 9 of the identified proteins were novel. Of these, 2 were increased by the administration of tocilizumab. These were alpha-1-antichymotrypsin complex (also termed SerpinA3 [serpin family A member 3]; UPI: P01011) and myeloblastin (also termed PRTN3 [proteinase 3]; UPI: 24158).

Seven proteins were decreased in the tocilizumab group as compared with the placebo group including the acute-phase proteins HAMP (hepcidin antimicrobial peptide) (UPI: P81172), IGFBP4 (insulin-like growth factor-binding protein 4) (UPI: P22692), and LBP (lipopolysaccharide-binding protein) (UPI: P18428), as well as VEGFA (vascular endothelial growth factor A) (UPI: P15692), C5A (complement component C5a anaphylatoxin) (UPI: P01031), and both the CCL23 (UPI: P55773) and its splice variant Ck-beta-8-1. Table S2 lists all proteins whose relative abundance differed between groups with an uncorrected P value <0.05.

**Temporal Profile of Discovered Proteins Over the Entire Time Course Measured by EIA**

Over the first 56 hours of serial samples during hospitalization, 6 of the 8 proteins (Ck-beta-8-1 included in the CCL23 EIA) were found to have significant differences in concentration between the tocilizumab and placebo groups when assessed by EIA (Figure 2). LBP, HAMP, and IGFBP4, as well as CCL23, were reduced throughout, in agreement with the SOMAscan assay. A total of 41 of the 58 patients (70.7%) in the tocilizumab group underwent PCI, and subanalysis showed that the reductions in LBP, IGFBP4, and CCL23 were only present in this group (Figure 2).

As found with the SOMAscan assay, tocilizumab induced a rapid increase in PRTN3 that was sustained for 56 hours, compared with no changes in the placebo group (Figure 2). This effect was seen regardless of whether the patients underwent PCI (Figure 2). In contrast to the proteomic data, however, the concentration of SerpinA3 as measured by EIA was decreased, rather than elevated, and there was no significant difference in the concentrations of VEGFA or C5A levels between the groups (Figure 2). Levels of all examined proteins were similar in the 2 groups at the 2 long-term follow-up time points (3 and 6 months).

**Associations of Discovered Proteins With Key Variables**

There were significant positive, but relatively modest, correlations found between CRP, hsTnT and NT-proBNP and LBP, HAMP, and IGFBP4; however, there was no effect of tocilizumab on these associations (Figure 3). In contrast, there was an association between CRP and PRTN3 in the placebo group, which was lost in the tocilizumab group. CCL23 was not associated with any of the variables, and PRTN3 was not associated with the myocardial markers hsTnT and NT-proBNP.

Whereas IL-6 was positively correlated with PRTN3, it was negatively correlated with HAMP, with the same pattern in both the placebo and tocilizumab groups (Figure 3). In contrast, a significant positive correlation between IL-6 and CCL23 was lost in the tocilizumab group.

The strongest correlations were found with neutrophil numbers. Circulating neutrophil concentrations

| Protein (SOMAscan Name) | Log Mean Difference Tocilizumab-Placebo (SE) | Unadjusted P Value | 95% CI | Bonferroni P Value | Benjamini-Hochberg P Value |
|-------------------------|---------------------------------------------|-------------------|-------|-------------------|--------------------------|
| IL-6 receptor subunit α | 1.25 (0.08)                                 | 2.31E-20          | 1.09  | 1.41              | 3.05E-17                 |
| α1-Antichymotrypsin complex/SerpinA3 | 0.36 (0.06) | 3.25E-07          | 0.24  | 0.47              | 0.0004                   |
| Hepcidin                | −0.68 (0.13)                                 | 2.41E-06          | −0.94 | −0.43             | 0.0032                   |
| IGFBP4                  | −0.22 (0.05)                                 | 2.71E-05          | −0.32 | −0.13             | 0.0357                   |
| Myeloblastin/PRTN3      | 0.65 (0.14)                                  | 3.76E-05          | 0.36  | 0.95              | 0.0496                   |
| VEGFA                   | −0.20 (0.04)                                 | 4.13E-05          | −0.29 | −0.11             | 0.0544                   |
| IL-6                    | 0.81 (0.18)                                  | 4.82E-05          | 0.45  | 1.18              | 0.0635                   |
| Ck-beta-8-1             | −0.36 (0.08)                                 | 5.00E-05          | −0.53 | −0.20             | 0.0658                   |
| CCL23                   | −0.28 (0.07)                                 | 0.0003            | −0.42 | −0.14             | 0.3448                   |
| C5A                     | −0.29 (0.07)                                 | 0.0004            | −0.44 | −0.14             | 0.4950                   |
| LBP                     | −0.23 (0.06)                                 | 0.0006            | −0.35 | −0.10             | 0.7392                   |

Benjamini-Hochberg false discovery rate set to 0.1. C5A indicates complement component C5a anaphylatoxin; CCL23, C-C motif chemokine ligand 23; IGFBP4, insulin-like growth factor-binding protein 4; IL, interleukin; LBP, lipopolysaccharide-binding protein; PRTN3 proteinase 3; SerpinA3, serpin family A member 3; VEGF, vascular endothelial growth factor A.
were positively correlated with the 3 acute-phase proteins (LBP, HAMP, and IGFBP4) in the placebo groups (Figure 3). However, in the case of LBP and HAMP, this association was lost in the tocilizumab group. Interestingly, a significant positive correlation in the placebo group between neutrophils and PRTN3 was inversed in the tocilizumab group.

As LBP has been shown to be associated with high-density lipoprotein cholesterol levels\(^1\)\(^1\) and tocilizumab has been shown to have a pronounced effect on lipids and in particular triglycerides,\(^1\)\(^2\) we evaluated associations between LBP and high-density lipoprotein cholesterol. First, we did not observe an effect of tocilizumab on triglycerides (area under the curve median 4.97 versus 5.00 mmol/L, versus placebo, respectively; \(P=0.80\)). Second, no correlation between the area under the curves of LBP and high-density lipoprotein cholesterol in the whole population \((r=-0.09, P=0.34)\) at any individual time point (all \(P>0.2\)) or for change from baseline to 48 hours postrandomization \((r=0.11, P=0.25)\) was observed. Evaluating these correlations within groups, ie, placebo versus tocilizumab or PCI versus non-PCI, revealed similar results.

**Functional Enrichment Analysis**

Employing WebGestalt we identified of 17 biological processes enriched by tocilizumab (Table 3). Of these enriched processes, notable ones including at least 1...
Figure 2. Plasma concentrations of proteins discovered by SOMAscan measured by enzyme immunoassay in the whole study cohort over time.

Plasma levels of LBP (lipopolysaccharide-binding protein), CCL23 (C-C motif ligand 23) (cross-reacts with Ck-beta-8-1), HAMP (hepcidin antimicrobial peptide), IGFBP4 (insulin-like growth factor-binding 4), PRTN3 (proteinase 3), SerpinA3 (serpin family A member 3), VEGF (vascular endothelial growth factor A), and CSA (complement component 5a anaphylatoxin) during hospitalization (baseline to 3 days) and follow-up (3 and 6 months) in patients with non–ST-segment–elevation myocardial infarction receiving placebo (n=59) or tocilizumab (n=58) and analyzed according to whether the patient did (n=88) or did not (n=29) undergo percutaneous coronary intervention (PCI) (n=88). Circles and bars represent estimated marginal means and 95% CIs normalized for baseline values. The $P$ value represents the effect of treatment.
of the 5 novel proteins we had identified were those related to acute inflammation such as response to tumor necrosis factor (CCL23, HAMP), cell chemotaxis (LBP, CCL23), and granulocyte migration (LBP, CCL23, PR3), as well as cardiac muscle development (HAMP).

**DISCUSSION**

Employing an aptamer-based proteomics approach on samples from the Norwegian tocilizumab NSTEMI trial cohort together with EIA measurements of these proteins across all time points, we have identified 5 proteins that are modulated by the administration of tocilizumab in NSTEMI. These results have revealed several interesting insights into the effects of tocilizumab treatment in NSTEMI and raised some important questions.

**Acute-Phase Proteins: LBP, HAMP, IGFBP4—Potential Secondary Mediators of IL-6 Inhibition During NSTEMI**

MI is associated with an acute-phase response, driven largely by IL-6 signaling. Thus, we have recently demonstrated that IL-6 blockade markedly lowers CRP in NSTEMI. Given this, it is not surprising that the SOMAscan assay identified other acute-phase proteins (LBP, HAMP, and IGFBP4), which were lower in the tocilizumab treatment group and were positively correlated with CRP. Furthermore, while a positive correlation was detected between LBP and HAMP and neutrophil counts during hospitalization (baseline to 3 days) in patients with non-ST-segment-elevation myocardial infarction receiving placebo (red circles, n=59) or tocilizumab (blue circles n=58), the regression lines and numbers reflect either placebo (red) or tocilizumab (blue).

**Figure 3.** Associations between newly identified proteins modulated by tocilizumab and parameters measured in the original study.

Dotplots showing associations between area under the curve (log-transformed) of plasma levels of LBP (lipopolysaccharide-binding protein), CCL23 (C-C motif ligand 23), hepcidin, IGFBP4 (insulin-like growth factor-binding 4), and PRTN3 (proteinase 3) with CRP (C-reactive protein), hsTnT (high-sensitivity troponin T), NT-proBNP (N-terminal pro-B-type natriuretic peptide), interleukin 6 (IL-6), and neutrophil counts during hospitalization (baseline to 3 days) in patients with non-ST-segment-elevation myocardial infarction receiving placebo (red circles, n=59) or tocilizumab (blue circles n=58). Black lines represent the regression line and the numbers in the bottom right the correlation coefficient for the whole group. If an interaction with tocilizumab was detected (green frames, see Statistical Analysis), the regression lines and numbers reflect either placebo (red) or tocilizumab (blue).
George et al. Proteomic Analysis of IL-6 Antagonism in NSTEMI from reflecting an attenuating effect of IL-6 antagonism on the acute-phase response, the downregulation of these molecules could also have a direct physiological impact.

HAMP is a key regulator of iron homeostasis and has recently been shown to be produced within the myocardium post-MI by both macrophages and cardiomyocytes. IL-6 has also been shown to induce monocyte gene expression of HAMP and may be responsible for its production in myocytes.

![Table 3](#)

| Biological Process                                      | Enrichment Ratio | P Value   | N  | n  | Proteins                                                                 |
|---------------------------------------------------------|------------------|-----------|----|----|--------------------------------------------------------------------------|
| Erythrocyte homeostasis                                 | 5.325            | 0.00051983| 20 | 6  | JAK2, EPO, GPI, VEGFA, TGFBR3, MAPK14                                    |
| Cellular response to chemical stimulus                  | 1.4005           | 0.00073273| 545| 43 | Not listed given large number. Includes CCL23, LBP, PR3, HAMP            |
| Response to TNF                                         | 2.5927           | 0.00079303| 89 | 13 | CCL23, HAMP, CCL24, JAK2, LTA, CXCL8, TNFRSF1A, TNFSF8, LT8, MAPK14, CCL4L1, OPN1, CXCL16 |
| Cell chemotaxis                                         | 2.2756           | 0.0012316 | 117| 15 | CCL23, LBP, CCL24, FGF18, CS, S100A9, PDGFR8, CXCL8, VEGFA, AZU1, IL-16, MAPK14, CCL4L1, CXCL16, IL-37 |
| Cardiac muscle tissue development                       | 3.4634           | 0.0013910 | 41 | 8  | HAMP, PDGFR8, VEGFA, BMPR1A, MAP2K4, FHRI1, TGFBR3, MAPK14              |
| Inductor of positive chemotaxis                         | 7.1              | 0.0014841 | 10 | 4  | CXCL8, VEGFA, AZU1, IL-16                                              |
| Coronary vasculature morphogenesis                      | 10.65            | 0.0015702 | 5  | 3  | PDGFR8, VEGFA, TGFBR3                                                   |
| Cardiac muscle cell development                         | 6.4545           | 0.0022344 | 11 | 4  | HAMP, PDGFR8, VEGFA, MAP2K4                                              |
| Positive regulation of organ growth                     | 4.9306           | 0.0023334 | 18 | 5  | HAMP, BMPR1A, FGF8, TGFBR3, MAPK14                                      |
| Monocyte differentiation                                | 6.6563           | 0.0077796 | 8  | 3  | APCS, CSFIR, VEGFA                                                       |
| Positive regulation of macromolecule biosynthetic process| 1.7634           | 0.0088122 | 184| 18 | LBP, JAK2, EPO, PDGFR8, H2AFZ, VEGFA, TNFRSF1A, AZU1, CCNA2, CDK2, TNFSF8, BMPR1A, MAP2K4, LT8, CAMK1, MAPK14, HJV, IL-17F |
| Positive regulation of tyrosine phosphorylation of STAT protein | 2.8239           | 0.0093213 | 44 | 7  | JAK2, CRLF1, EPO, CSFIR, VEGFA, TNFRSF1A, CLCF1                           |
| Granulocyte migration                                   | 2.3843           | 0.0099917 | 67 | 9  | CCL23, LBP, PRTN3, CCL24, S100A9, CXCL8, MAPK14, CCL4L1, IL-37         |
| Aorta morphogenesis                                     | 5.9167           | 0.011205  | 9  | 3  | PDGFR8, BMPR1A, FGF8                                                    |
| Regulation of nitrogen compound metabolic process       | 1.2723           | 0.012931  | 572| 41 | Not listed given large number. Includes CCL23, LBP, PRTN3, HAMP, IGFBP4 |
| Cell migration                                          | 1.4604           | 0.014433  | 316| 26 | Not listed given large number. Includes CCL23, LBP, PRTN3               |
| Negative regulation of neuron death                     | 2.485            | 0.018581  | 50 | 7  | JAK2, CRLF1, EPO, GPI, MAP2K4, FGF8, CLCF1                               |

Seventeen gene ontology biological processes were identified as enriched in the blood in patients following tocilizumab treatment. AZU1 indicates azurocidin 1; BMPR1A, bone morphogenetic protein receptor type 1A; CAMK1, calcium/calmodulin-dependent protein kinase 1; CCL23, C-C motif chemokine ligand 23; CCL24, C-C motif chemokine ligand 24; CCL4L1, C-C motif chemokine ligand 4-like 1; CCNA2, cyclin A2; CDK2, cyclin-dependent kinase 2; CLCF1, cardiopotin-like cytokine factor 1; CRLF1, cytokine receptor-like factor 1; CSF1R, colony-stimulating factor 1 receptor; CXCL8, C-X-C motif chemokine ligand 8; EPO, erythropoietin; FGFR8, fibroblast growth factor 8; GPI, glycosylphosphatidylinositol; H2AFZ, H2A histone family, member Z; HAMP, hepcidin antimicrobial peptide; HJV, hemouvelin; IGFBP4, insulin-like growth factor-binding protein 4; IL17F, interleukin 17F, IL37, interleukin 37; JAK2, Janus kinase 2; LBP, lipopolysaccharide-binding protein; LT8, lymphotoxin β; MAP2K4, mitogen-activated protein kinase 4; MAPK14, mitogen-activated protein kinase 14; N, number of proteins associated with gene ontology term in SOMAscan assay data set; n, number of proteins associated with gene ontology term in SOMAscan assay data set and the query list of differentially expressed proteins identified following tocilizumab treatment; PDGFRB, platelet-derived growth factor receptor β; PRTN3, proteasine 3; S100A9, S100 calcium-binding protein A9; TNFRSF1A, tumor necrosis factor receptor superfamily 1A; TNFSF8, tumor necrosis factor superfamily member 8; and VEGFA, vascular endothelial growth factor A.
by iron overload. However, conversely, HAMP has also been shown to contribute to plaque destabilization via activation of macrophages, and therefore there may also be advantages to its downregulation post-MI.

LBP, which plays a key role in the immune response to gram-negative bacteria, has also recently been identified as a novel component of atherosclerotic plaques that is released into the circulation after plaque rupture and is associated with increased cardiovascular risk. LBP has been shown to closely associate with high-density lipoprotein cholesterol and tocilizumab has pronounced effects on lipids, but we were unable to demonstrate any associations between tocilizumab, LBP, and lipids. In the functional analysis, LBP was associated with multiple enriched biological processes including cell and granulocyte chemotaxis/migration, suggesting that it may have a significant role in mediating inflammation post-MI. Indeed, it has been suggested that LBP may have a direct role in myocardial inflammation post-MI via CD14/Toll-like receptor 4–associated pathways.

IGFBP4, a binding protein that prolongs the half-life of insulin-like growth factor, may also play a role in acute MI. Insulin-like growth factor stimulation of macrophages results in inflammatory cytokine release and it has also been shown to play a role in plaque development.

Therefore, given the evidence from the functional analysis and emerging literature, it is possible that the reduction in the 3 identified acute-phase proteins may contribute to the anti-inflammatory effects of IL-6 inhibition in NSTEMI.

CCL23: a Monocyte Chemoattractant That Could Contribute to the Anti-Inflammatory Effect of Tocilizumab in NSTEMI

CCL23 is a member of the CC chemokine family and is involved in leukocyte trafficking and activation. For example, it has been shown to act as both a monocyte chemoattractant and to stimulate the release of monocyte chemoattractant protein-1 and tumor necrosis factor from these cells. A specific role for CCL23 in ischemic heart disease is supported by increased expression in atherosclerotic lesions and in the circulation in patients with atherosclerosis, and by its association with cardiovascular outcomes. However, its role in MI has not previously been studied and this is the first study to our knowledge to suggest a direct link between IL-6 signaling and CCL23. Given that monocytes play a key role in the inflammatory response during plaque destabilization and post-MI maladaptive remodeling, the suppression of CCL23 may be a key mechanism by which tocilizumab beneficially modifies the inflammatory milieu post-MI and warrants further investigation.

However, although CCL23 was associated with several enriched biological processes related to inflammation, including response to tumor necrosis factor, cell chemotaxis/cell migration, and granulocyte migration, IL-6 inhibition had a variable effect on proteins associated with these processes. For example, with regards to cell chemotaxis (Table S3), certain proteins were downregulated in the same manner as CCL23, including the cytokine IL-37 and chemokine CXCL (C-X-C motif chemokine ligand 16. However, others were elevated, such as the cytokine/chemokines CXCL8, CCL24, CCL4L1, and IL-16. Given this, tocilizumab likely has pleiotropic effects on chemotaxis post-MI and the overall net effect on cell trafficking is therefore difficult to discern.

PRTN3 is Related to Neutropenia During Tocilizumab Therapy in NSTEMI

A major finding in our study was the marked and early increase in PRTN3 during IL-6 inhibition. PRTN3 is a serine protease mainly expressed by neutrophils, but may also be expressed by endothelial cells. The associated proteases myeloperoxidase and azurocidin are also elevated in the SOMAscan assay but did not reach the multiplicity adjusted threshold of significance (Table S2). Although the mechanism for tocilizumab-induced neutropenia is not firmly established, it may occur rapidly within few hours, indicating limited involvement of bone marrow. In patients with rheumatoid arthritis, the neutropenia induced by tocilizumab has been attributed to the inhibition of antiapoptotic actions of IL-6 on activated neutrophils, and evidence for a proapoptotic effect of tocilizumab treatment has been demonstrated in vitro. Thus, the rapid increase in PRTN3 could be related to its release from apoptotic neutrophils. This is supported by the interaction analysis, which revealed that while neutrophils and PRTN3 were positively correlated in the placebo group, they were negatively correlated in the tocilizumab group. In addition, PRTN3 itself may also directly stimulate neutrophil apoptosis, which may further increase PRTN3 release. As neutrophil apoptosis is a key process in the resolution of inflammation, we speculate that the proapoptotic effects of PRTN3 on neutrophils could contribute to the beneficial effects of tocilizumab following MI.

As with other neutrophil serine proteases, however, there are also many potential deleterious effects associated with its release in the context of MI. Furthermore, antibodies against PRTN3 and myeloperoxidase are associated with antineutrophil cytoplasmic antibody–related vasculitis. Thus, this important and interesting finding warrants further investigation in
order to establish the underlying mechanism and to understand whether the increased levels of PRTN3 may augment or mitigate the beneficial effects of IL-6 inhibition in NSTEMI. From a clinical perspective, it would also be important to assess whether there is an increased risk of developing antineutrophil cytoplasmic antibody autoantibodies in patients who receive tocilizumab in the context of MI.

Is IL-6 Antagonism Only Likely to Be of Benefit in Patients With Reperfused MI?

In the Norwegian tocilizumab NSTEMI trial, the area under the curve for hsTnT during hospitalization was significantly lower in the tocilizumab arm (159 versus 234 ng/L per h, \(P=0.07\)); however, subanalysis of the study demonstrated that this reduction was only observed in the group of patients who underwent PCI.\(^7\) Similarly, in this follow-up study, the reductions in LBP, IGFBP4, and CCL23 were also only observed in the group that underwent PCI. These data suggest that IL-6 antagonism may have more significant anti-inflammatory and therapeutic effects in the setting of reperfusion. This is possibly because reperfusion is associated with a substantially more robust inflammatory response compared with ischemia alone,\(^33\) characterized by both increased myocardial IL-6 mRNA transcription\(^34\) and plasma concentrations.\(^35\) The ASSAIL-MI (Assessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction) trial,\(^36\) which has enrolled patients with ST-segment–elevation MI undergoing primary PCI, will help determine whether targeting IL-6 in the context of early reperfusion is likely to be of therapeutic benefit.

Study Strengths and Limitations

Our study has several strengths including the application of a proteomics platform with over 1000 analytes, corroboration of the assay with proteins measured in the original study, and verification of SOMAscan findings by EIA across the whole time course. However, there are some notable limitations and caveats.

Although significant, the correlation between EIA and SOMAscan measures of IL-6, sIL-6R, and sgp130 were relatively weak (\(r=0.49–0.52\)), whereas the correlation between measures of CRP were strong (\(r=0.93\)). This may reflect the accuracy and sensitivity of assays used for these analytes in the original study. Whereas CRP was the primary outcome and measured with a high-sensitivity, automated, clinical-grade immunoturbidimetric assay (Roche Diagnostics) with a within-run coefficient of variance of \(\approx1.5\%\) and between-run coefficient of variance of 2.5%\(^37\) the other assays were research-grade EIAs (R&D Systems), which are less accurate and have higher within- and between-run coefficient of variance values of up to 10%.\(^38\)

Furthermore, although 8 of the 11 proteins that were identified by the SOMAscan proteomics platform were confirmed to be significantly altered by tocilizumab over the entire study time course by EIA, this was not the case for SerpinA3, VEGFA, and C5A. This may be attributable to the time point selected for SOMAscan not being reflective of the entire time course, technical variability in the assays employed, or biological instability of some of the measured analytes.\(^39\)

We only performed the initial SOMAscan assay on samples from 48 patients (24 tocilizumab, 24 controls) at a single time point. Given the small sample size, and the liberal adjustment for multiplicity that was selected (Benjamini-Hochberg with a false discovery rate set to 0.1), there is a chance that we selected false-positive proteins for further study. Conversely, given the small sample size, there may be several important false-negative proteins within this group that are significantly regulated by IL-6, and increasing the number of samples would have given us greater power to identify them. Furthermore, the use of samples from the patients who underwent PCI for the initial proteomics may have biased the discovery of proteins towards those that are only modulated in this context. The list of 50 proteins that were different between the 2 groups with an uncorrected \(P\) value <0.05 is included in Table S2. Our study did not have any hard outcome measures and we are not proposing that any of the markers represent prognostic biomarkers in NSTEMI.

Finally, to perform the network analysis using WebGestalt, we included all of the proteins, which were significantly altered by tocilizumab, including those that were not significant after adjustment for multiplicity. Furthermore, these proteins were not subsequently measured in the whole cohort by EIA. Therefore, the results of the network analysis must be considered complementary and hypothesis-generating and further work is required to understand the effects of IL-6 inhibition on the wider proteome post-MI.

CONCLUSIONS

We have hitherto been unable to identify cytokines or other molecules that could contribute to the benefit of tocilizumab in our NSTEMI study.\(^40\)\(^41\) Herein, however, by employing a powerful, aptamer-based proteomics platform, we have identified several proteins that are significantly modulated by the administration of tocilizumab in patients with NSTEMI, particularly in the context of PCI, and that could potentially be secondary downstream mediators of the beneficial effect of tocilizumab in this cohort. The findings with regard to PRTN3 and CCL23 are particularly noteworthy and warrant further investigation. As the interest in targeting inflammatory cytokines in CAD grows, understanding
the consequence of this approach in detail may lead to the identification of new targets and more effective therapeutics.

ARTICLE INFORMATION
Received December 13, 2019; accepted April 14, 2020.

Affiliations
From the Department of Clinical Pharmacology (M.J.G.), Centre for Cardiovascular Genetics, Institute of Cardiovascular Science (J.G.-H., J.P., J.E., A.D.H.), and Functional Gene Annotation, Preclinical and Fundamental Science, Institute of Cardiovascular Science (R.L.), University College London, London, United Kingdom; Clinic of Cardiology, St Olav’s Hospital, Trondheim, Norway (O.K., R.W.); Department of Circulation and Medical Imaging, Norwegian University of Science and Technology NTNU, Trondheim, Norway (O.K., R.W.); K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromso, Tromso, Norway (P.A., T.U.); Research Institute of Internal Medicine (P.A., T.U.), Department of Cardiology (P.A., L.G.), and Section of Clinical Immunology and Infectious Diseases (P.A.), University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine (P.A., L.G., T.U.), K.G. Jebsen Centre of Inflammatory Research (P.A.), and K.G. Jebsen Cardiac Research Centre and Centre for Heart Failure Research (L.G.), University of Oslo, Norway; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway (J.K.D.); Department of Infectious Diseases, St Olav’s Hospital, Trondheim University Hospital, Trondheim, Norway (U.K.D.); Institute of Health Informatics, University College London, London, United Kingdom (J.P.C.); Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), Boston, MA (J.P.C.).

Acknowledgments
We are grateful to SOMAlogic for their assistance in performing the SOMAscan assay.

Sources of Funding
This study was funded by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. MJG was funded by a Wellcome Trust Clinical Research Training Fellowship during the project. ADH is an NIHR senior investigator.

Disclosures
None.

Supplementary Materials
Tables S1–S3
Figure S1

REFERENCES

1. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DJ, Holmes MV, Kuchenbaecker KB, Engmann JEL, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379:1214–1224.

2. Cai T, Zhang Y, Ho YL, Link N, Sun J, Huang J, Cai TA, Damrauer S, Ahuja Y, Honerlaw J, et al. Association of interleukin 6 receptor with cardiovascular disease effects of interleukin 6 receptor blocking therapy: a phenome-wide association study. JAMA Cardiol. 2018;3:849–857.

3. Fanola CL, Morrow DA, Cannon OP, Jarolim P, Lukas MA, Bode C, Hochman JS, Gooch EN, Braunwald E, O’Donoghue ML. Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (stabilization of plaque using darapladib-thrombolysis in myocardial infarction 52) Trial. J Am Heart Assoc. 2017;6:e005637. 10.1161/JAHA.117.005637

4. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107–2113.

5. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959–3964.

6. Ricker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicola J, Koening W, Anker SD, et al: CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.

7. Kleveland O, Kunzst G, Brattle M, Ueland T, Broch K, Holte E, Michelsen AE, Bendz B, Amundsen BH, Espevik T, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37:2406–2413.

8. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J, Dalby AB, Eaton BE, Fitzwater T, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE. 2010;5:e15004.

9. Liao Y, Wang J, Jaehng EJ, Shi Z, Zhang B. Webgestalt 2019: gene set analysis toolkit with revamped Uis and APIs. Nucleic Acids Res. 2019;47W199–W205.

10. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25–29.

11. Wurfl MM, Wright SD. Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipopolysaccharides. Prog Clin Biol Res. 1995;392:287–295.

12. Strange AC, Biosoendial RJ, Kootse RS, Schulte DM, Dallinga-Thie GM, Levels JH, Koks M, Vos K, Tas SW, Tietje UG, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229:174–181.

13. Bode JC, Albrecht U, Haussinger D, Heinrich PC, Schaper F. Hepatic acute phase proteins–regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-kappaB-dependent signaling. Eur J Cell Biol. 2012;91:496–505.

14. Sasai M, Isyo Y, Mizukami T, Tomosugii N, Sambe T, Miyazaki A, Suzuki H. Potential contribution of the hepatic-macrophage axis to plaque vulnerability in acute myocardial infarction in human. Int J Cardiol. 2017;227:114–121.

15. Isoda M, Hanawa H, Watanabe R, Yoshida T, Toba K, Yoshida K, Kojima M, Otaki M, Kao K, Ding L, et al. Expression of the peptide hormone hepcidin increases in cardiomyocytes under myocarditis and myocardial infarction. J Nutr Biochem. 2010;21:749–756.

16. Lakhal-Littleton S. Cardiomyocyte hepcidin: from intracellular iron homeostasis to physiological function. Vitam Horm. 2019;110:189–200.

17. Simonis G, Mueller K, Schwarz P, Wiedemann S, Adler G, Strasser RH, Kulozik H. The iron-regulatory peptide hepcidin is upregulated in the ischemic and in the remote myocardium after myocardial infarction. Peptides. 2010;31:1786–1790.

18. Li JJ, Meng X, Si HP, Zhang C, Lv HK, Zhao YX, Yang JM, Dong M, Zhang K, Liu SX, et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythropoietic dysregulation. Arterioscler Thromb Vasc Biol. 2012;32:1159–1166.

19. Lee R, Fischer R, Charles PD, Adlam D, Vali A, Di Gleria K, Khairbaha RK, Choudhury RP, Antoniades C, Kessler BM, et al. A novel workflow combining plaque imaging, plaque and plasma proteomics identifies biomarkers of human coronary atherosclerotic plaque disruption. Clin Proteomics. 2017;14:22.

20. Ganz P, Heidecker B, Hveem K, Jonasson C, Kato S, Segal MR, Sterling DG, Williams SA. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. 2016;315:2532–2541.

21. Conover CA, Mason MA, Bale LK, Harrington SC, Nyegaard M, Ovlig C, Overgaard MT. Transgenic overexpression of pregnancy-associated plasma protein-A in murine arterial smooth muscle accelerates atherosclerotic lesion development. Am J Physiol Heart Circ Physiol. 2010;299:H284–H291.

22. Harrington SC, Simari RD, Conover CA. Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet. Circ Res. 2007;100:1696–1702.

23. Kim GS, Kang JH, Cho HR, Blankenship TN, Erickson KL, Kawada T, Yu R. Potential involvement of CCL23 in atherosclerotic lesion formation.

George et al
Proteomic Analysis of IL-6 Antagonism in NSTEMI

J Am Heart Assoc. 2020;9:e015628. DOI: 10.1161/JAHA.119.015628

12
formation/progression by the enhancement of chemotaxis, adhesion molecule expression, and MMP-2 release from monocytes. *Inflamm Res.* 2011;60:889–895.

24. Hulsmans M, Sam F, Nahrendorf M. Monocyte and macrophage contributions to cardiac remodeling. *J Mol Cell Cardiol.* 2016;93:149–155.

25. Mayet WJ, Csermok E, Szymkowiak C, Gross WL, Meyer zum Büschenfelde KH. Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener’s granulomatosis. *Blood.* 1993;82:1221–1229.

26. Nagamine R, Chen W, Hara T, Kondo K, Sugioa Y. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases. *Mod Rheumatol.* 2009;19:348–350.

27. Nakamura I, Ōmata Y, Naito M, Ito K. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. *J Rheumatol.* 2009;36:459–460.

28. Szalay B, Acs L, Vásárhelyi B, Kovács L, Balog A. Successful use of tocilizumab in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapy. *J Clin Rheumatol.* 2011;17:377–379.

29. Loison F, Zhu H, Karatepe K, Kasorn A, Liu P, Ye K, Zhou J, Cao S, Gong H, Jenne DE, et al. Proteinase 3-dependent caspase-3 cleavage modulates neutrophil death and inflammation. *J Clin Invest.* 2014;124:4445–4458.

30. Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek A, Wieczorek M, Kroon H, Leimer AH, Cheronis J. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1 beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. *Proc Natl Acad Sci USA.* 1999;96:6261–6266.

31. Ramah A, Patston PA. Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases. *Arch Biochem Biophys.* 2002;397:77–83.

32. Gapud EJ, Seo P, Antochos B. ANCA-associated vasculitis pathogenesis: a commentary. *Curr Rheumatol Rep.* 2017;19:15.

33. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. *Cardiovasc Res.* 2002;53:31–47.

34. Kukielka GL, Youker KA, Michael LH, Kumar AG, Ballantine CM, Smith CW, Entman ML. Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium. *Mol Cell Biochem.* 1995;147:5–12.

35. Imaizumi T, Nejima J, Kuchki K, Takeda S, Seino Y, Tanaka K, Takano T. Dynamics and source of endothelin-1 and interleukin-6 following coronary reperfusion in patients with acute myocardial infarction. *J Nippon Med Sch.* 2007;74:131–147.

36. ASeSSing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial - Full Text View - ClinicalTrials.gov [Internet]. Available at: https://clinicaltrials.gov/ct2/show/NCT03004703. Accessed February 28, 2018.

37. eLabDoc - Roche Dialog [Internet]. Available at: https://dialog1.roche.com/gb/en_gb/elabDoc. Accessed October 10, 2019.

38. R&D Systems ELISA Kits: Quality Manufacturing and Evaluation of Performance [Internet]. www.rndsystems.com. Available at: https://www.rndsystems.com/products/elisas-quality-manufacturing-and-performance-evaluation. Accessed October 10, 2019.

39. Candia J, Cheung F, Kottarav Y, Fantoni G, Sellers B, Griesman T, Huang J, Stuccio S, Zingone A, Ryan BM, et al. Assessment of variability in the SOMAscan assay. *Sci Rep.* 2017;7:14248.

40. Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K, Holte E, Ryan L, Amundsen BH, Bendz B, et al. Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction. *Int J Cardiol.* 2018;271:1–7.

41. Holte E, Kleveland O, Ueland T, Kunszt G, Bratlie M, Broch K, Michelsen AE, Bendz B, Amundsen BH, Aakhus S, et al. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. *Heart.* 2017;103:1521–1527.
Table S1. Antibodies used for EIA.

| Protein                              | Supplier       | Antibody Capture | Antibody Detection |
|--------------------------------------|----------------|------------------|--------------------|
| Lipopolysaccharide-binding protein   | R&D systems    | Mouse, monoclonal| Goat, polyclonal   |
| C-C motif chemokine ligand 23        | R&D systems    | Mouse, monoclonal| Goat, polyclonal   |
| Hepcidin                             | R&D systems    | Rabbit, monoclonal| Rabbit, monoclonal|
| Insulin like growth factor binding protein 4 | R&D systems    | Mouse, monoclonal| Goat, polyclonal   |
| Vascular endothelial growth factor A | R&D systems    | Mouse, monoclonal| Goat, polyclonal   |
| Myeloblastin/PRTN3                   | R&D systems    | Mouse, monoclonal| Mouse, monoclonal  |
| Alpha-1-antichymotrypsin complex/Serpin A3 | Sino Biological| Rabbit, monoclonal| Rabbit, monoclonal |
Table S2. All proteins identified by the SOMAscan assay with a p-value of <0.05.

| Protein (SOMAscan name)                          | Log Mean diff TCZ-placebo | SE   | p value     |
|------------------------------------------------|---------------------------|------|-------------|
| Interleukin-6 receptor subunit alpha            | 1.25                      | 0.08 | 2.31E-20    |
| Alpha-1-antichymotrypsin complex                | 0.36                      | 0.06 | 3.25E-07    |
| Hepcidin                                        | -0.68                     | 0.13 | 2.41E-06    |
| Insulin-like growth factor-binding protein 4    | -0.22                     | 0.05 | 2.71E-05    |
| Myeloblastin                                    | 0.65                      | 0.14 | 3.76E-05    |
| Vascular endothelial growth factor A            | -0.20                     | 0.04 | 4.13E-05    |
| Interleukin-6                                   | 0.81                      | 0.18 | 4.82E-05    |
| Ck-beta-8-1                                     | -0.36                     | 0.08 | 5.00E-05    |
| C5a anaphylatoxin                               | -0.29                     | 0.07 | 0.000376    |
| Lipopolysaccharide-binding protein              | -0.23                     | 0.06 | 0.000561    |
| C-type lectin domain family 4 member M          | -0.11                     | 0.03 | 0.001810    |
| Mitogen-activated protein kinase 14             | 0.25                      | 0.08 | 0.001927    |
| Azurocidin                                      | 0.20                      | 0.06 | 0.002362    |
| Protein S100-A9                                  | -0.22                     | 0.07 | 0.003216    |
| Kin of IRRE-like protein 3                      | 0.19                      | 0.06 | 0.003261    |
| Growth arrest-specific protein 1                | -0.12                     | 0.04 | 0.003322    |
| Complement decay-accelerating factor            | -0.14                     | 0.05 | 0.003765    |
| Macrophage colony-stimulating factor 1 receptor | 0.25                      | 0.08 | 0.005122    |
| Tyrosine-protein kinase JAK2                    | -0.15                     | 0.05 | 0.006712    |
| C-C motif chemokine 4-like                      | 0.27                      | 0.10 | 0.008218    |
| Serum amyloid P-component                       | -0.12                     | 0.04 | 0.008226    |
| Glucose-6-phosphate isomerase                   | 0.37                      | 0.14 | 0.009625    |
| Interleukin-17F                                 | -0.19                     | 0.07 | 0.009714    |
| Histone H2A.z                                   | 0.51                      | 0.19 | 0.009800    |
|Gene Name                                         | Value 1 | Value 2 | p-value  |
|-------------------------------------------------|---------|---------|----------|
|Immunoglobulin gamma Fc region receptor III-B    | 0.24    | 0.09    | 0.010483 |
|Cerebral dopamine neurotrophic factor            | -0.21   | 0.08    | 0.010806 |
|Myeloperoxidase                                  | 0.26    | 0.10    | 0.011464 |
|Tumor necrosis factor receptor superfamily member 1A | -0.18   | 0.07    | 0.011650 |
|Cystatin-S                                       | -0.25   | 0.10    | 0.015080 |
|Somatostatin-28                                  | -0.13   | 0.05    | 0.017296 |
|Bone morphogenetic protein receptor type-1A      | -0.16   | 0.07    | 0.020002 |
|Interleukin-16                                   | 0.20    | 0.08    | 0.020767 |
|Interleukin-8                                    | 0.18    | 0.08    | 0.022531 |
|Copine-1                                         | 0.33    | 0.14    | 0.022640 |
|beta-adrenergic receptor kinase 1                | 0.41    | 0.18    | 0.023288 |
|Inter-alpha-trypsin inhibitor heavy chain H4     | -0.09   | 0.04    | 0.023431 |
|Hemojuvelin                                      | -0.17   | 0.07    | 0.023521 |
|Dynactin subunit 2                               | -0.11   | 0.05    | 0.024462 |
|Transforming growth factor beta receptor type 3  | -0.13   | 0.06    | 0.026103 |
|Ephrin-A4                                        | -0.14   | 0.06    | 0.026112 |
|C-X-C motif chemokine 16                         | -0.11   | 0.05    | 0.028414 |
|Dual specificity mitogen-activated protein kinase kinase 4 | -0.20   | 0.09    | 0.029091 |
|Erythropoietin                                   | -0.25   | 0.11    | 0.029717 |
|Moesin                                           | -0.25   | 0.11    | 0.030028 |
|Cardiotrophin-like cytokine factor 1 Complex     | 0.20    | 0.09    | 0.032515 |
|L-lactate dehydrogenase B chain                  | 0.24    | 0.11    | 0.034243 |
|Lymphotoxin alpha1:beta2                        | 0.11    | 0.05    | 0.036623 |
|Platelet-derived growth factor receptor beta     | -0.28   | 0.13    | 0.036766 |
|Cyclin-dependent kinase 2:Cyclin-A2 complex      | 0.20    | 0.10    | 0.039800 |
|Fibroblast growth factor 18                      | 0.42    | 0.20    | 0.040492 |
|Tropomyosin beta chain                           | -0.15   | 0.07    | 0.041355 |
|Proteasome subunit alpha type-1                  | 0.10    | 0.05    | 0.044684 |
|Complement component C6                          | -0.08   | 0.04    | 0.044729 |
|Tumor necrosis factor ligand superfamily member 8 | 0.11    | 0.05    | 0.044754 |
| Protein Name                                                      | Value 1 | Value 2 | p-value       |
|------------------------------------------------------------------|---------|---------|---------------|
| Protein FAM107A                                                  | -0.16   | 0.08    | 0.045972      |
| Fibroblast growth factor 8 isoform A                            | 0.20    | 0.10    | 0.046155      |
| C-C motif chemokine 24                                           | 0.25    | 0.12    | 0.046868      |
| Calcium/calmodulin-dependent protein kinase type 1              | -0.19   | 0.09    | 0.047212      |
| Desert hedgehog protein N-product                                | 0.20    | 0.10    | 0.049036      |
| Interleukin-37                                                   | -0.11   | 0.06    | 0.049805      |
Table S3. Proteins associated with the enriched GO term ‘cell chemotaxis’.

| Protein                                      | Effect of TCZ | Protein class               |
|----------------------------------------------|---------------|-----------------------------|
| Cell Chemotaxis                              |               |                             |
| C-C motif chemokine ligand 23 (CCL23)        | Reduced       | Chemokine                   |
| LPS binding protein (LBP)                    | Reduced       | Acute Phase Protein         |
| Complement C5 (C5)                           | Reduced       | Complement                  |
| S100 calcium binding protein A9 (S100A9)     | Reduced       | Calcium-binding protein     |
| Platelet derived growth factor receptor beta (PDGFRB) | Reduced    | Growth factor               |
| Vascular Endothelial Growth factor A (VEGFA) | Reduced       | Growth Factor               |
| Interleukin 37 (IL37)                        | Reduced       | Cytokine                    |
| C-X-C motif chemokine ligand 16 (CXCL16)     | Reduced       | Chemokine                   |
| Fibroblast growth factor 18 (FGF18)          | Elevated      | Growth Factor               |
| Azurocidin 1 (AZU1)                          | Elevated      | Serine Protease             |
| C-C motif chemokine ligand 24 (CCL24)        | Elevated      | Chemokine                   |
| C-X-C motif chemokine ligand 8 (CXCL8)       | Elevated      | Chemokine                   |
| C-C motif chemokine ligand 4 like 1 (CCL4L1) | Elevated      | Chemokine                   |
| Mitogen-activated protein kinase 14 (MAPK14) | Elevated      | Kinase                      |
| Interleukin 16 (IL16)                        | Elevated      | Chemokine                   |
**Figure S1. Selection of SOMAscan data transformation method.** Proteomic transformations assessing the distribution of the a) proportion of outliers b) skewness and c) kurtosis. This was performed with data from all proteins in the 1.3k SOMAscan assay (before proteins removed in the quality-control process). The X axis refers to the 1.3k SOMAscan proteins. The Y axis denotes, from top to bottom to the proportion of outliers, skewness and kurtosis. Vertical red line means the division of half of total number of proteins (N=659).
